Amgen Inc. AMGN on Saturday released interim Phase 3 trial results showing that Imdelltra, evaluated in combination with ...

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance ...

Amgen's Imdelltra used in combination with AstraZeneca's immunotherapy Imfinzi reduced the risk of death by 58% compared to the Astra drug alone in patients with extensive-stage ...

Both of these biotech stocks could be appealing to income investors.

Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock ...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Amgen (AMGN) closed at $439.26 in the latest trading session, marking a -1.79% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.52%. Meanwhile, the Dow ...

Imdelltra sales more than tripled from about $80 million in Q1 2025 to $260 million in Q1 2026, and Q2 sales jumped 115% to $288 million. That's a real launch. It's also about 2.9% of the $10.05 ...

Amgen drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read an analysis of AMGN stock now.

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning. Amgen ...

The US FDA on Tuesday warned Amgen that a promotional video for its colorectal cancer drug ​was misleading because it ...

Amgen discovers and delivers medicines for serious diseases across several core areas, including inflammation, rare disease, and oncology. Its massive scale allows it to distribute products to roughly ...